		Type: Drug Guideline	Document reference: 6368	Manual Classification: Waikato DHB Drug Guidelines
Title: Lidocaine 1% for Neonates			Effective date: 24 February 2021	
Facilitator <small>sign/date</small>	Authorised <small>sign/date</small>	Authorised <small>sign/date</small>	Version: 1	Page: 1 of 2
<i>Kerrie Knox</i> Pharmacist	<i>Jutta van den Boom</i> Clinical Director NICU	<i>John Barnard</i> Chair Medicines & Therapeutics	Document expiry date: 24 February 2024	

© Waikato DHB, February 2021

BRIEF ADMINISTRATION GUIDE

For detailed information refer to lidocaine monograph in the [NZ Formulary for Children](#)

Note: lidocaine is also known as lignocaine

Indications: • local anaesthesia prior to intercostal catheter insertion

Note: lidocaine IV has also been used to control seizures and ventricular arrhythmias unresponsive to other agents however this use is not covered in this guideline

Route: Subcutaneous (for local anaesthesia)

- Supplied as lidocaine hydrochloride anhydrous 1% (50 mg / 5 mL)

Dose: 3 mg/kg (0.3 mL/kg)

Preparation and administration

- Draw up prescribed dose of lidocaine 1%. Using a fine needle and minimum number of injections (25G in 2.5cm length standard or 29G on 1mL 'tuberculin' syringes when only a small area of infiltration required).
- Infiltrate the lidocaine at the insertion site (between 4th and 5th intercostal space) in the anterior axillary line and allow enough time for local anaesthesia to take place

Note:

- Warming the lidocaine solution to near body temperature can diminish pain of infiltration.
- Do not use with adrenaline

Monitoring

- No specific monitoring is required for lidocaine. Standard monitoring as per NICU protocol.

Storage and Stability


- Discard any remaining solution from the ampoule immediately after use

Competency for administration

This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Waikato DHB Generic Medicine Management.

References

- New Zealand Formulary for Children (NZFC). Lidocaine. Accessed December 2020. Available from: https://www.nzfchildren.org.nz/nzf_7057
- The Australian Injectable Drugs Handbook, 8th edition. SHPA 2020.

	Document reference: 6368	Effective date: 24 Feb 2021	Expiry date: 24 Feb 2024	Page: 2 of 2
	Title: Lidocaine 1% for neonates	Type: Drug Guideline	Version: 1	Authorising initials:

- King Edward Memorial Hospital & Perth Children's Hospital Neonatology lidocaine guideline. Available from: <https://www.kemh.health.wa.gov.au/~media/Files/Hospitals/WNHS/For%20health%20professionals/Clinical%20guidelines/NCCU/Drug%20Protocols/Lignocaine.pdf>
- Truven Health Analytics Inc. Pediatrics and Neofax®. Lidocaine - CNS monograph. Accessed December 2020. Available from: <http://www.micromedexsolutions.com>.
- Phelps SJ, Hagemann TM, Lee KR, Thompson AJ. The Teddy Bear Book: Pediatric Injectable Drugs. 11th edition. American Society of Health-System Pharmacists; 2018.
- Package insert for Lidocaine-Clarix. Multichem NZ Ltd, 10 January 2017
- The Royal Children's Hospital Melbourne. Paediatric Injectable Guidelines. Accessed December 2020. Available from: <https://pig.rch.org.au>.
- Auckland DHB clinical guideline Local anaesthetic for minor procedures. September 2019. Available from <https://www.starship.org.nz/guidelines/local-anaesthetic-for-minor-procedures/>
- Canterbury DHB Neonatal Services. Lignocaine Drug Information Sheet. March 2016. Available from <https://www.cdhb.health.nz/wp-content/uploads/b38c3bcc-lignocaine.pdf>

Note: Printed copies are only valid on the day of printing – they are not controlled and may not be the current version in use. Please refer to the online version.

Disclaimer: *This document has been developed by Waikato District Health Board specifically for its own use. Use of this document and any reliance on the information contained therein by any third part is at their own risk and Waikato District Health Board assumes no responsibility whatsoever.*